Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.

MLA

Kantarjian, Hagop, et al. “Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukaemia: A Single-Arm, Phase 2 Study.” The Lancet. Oncology, vol. 19, no. 2, Feb. 2018, pp. 240–48. EBSCOhost, https://doi.org/10.1016/S1470-2045(18)30011-1.

APA

Kantarjian, H., Ravandi, F., Short, N. J., Huang, X., Jain, N., Sasaki, K., Daver, N., Pemmaraju, N., Khoury, J. D., Jorgensen, J., Alvarado, Y., Konopleva, M., Garcia-Manero, G., Kadia, T., Yilmaz, M., Bortakhur, G., Burger, J., Kornblau, S., Wierda, W., … Jabbour, E. (2018). Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. The Lancet. Oncology, 19(2), 240–248. https://doi.org/10.1016/S1470-2045(18)30011-1

Chicago

Kantarjian, Hagop, Farhad Ravandi, Nicholas J Short, Xuelin Huang, Nitin Jain, Koji Sasaki, Naval Daver, et al. 2018. “Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukaemia: A Single-Arm, Phase 2 Study.” The Lancet. Oncology 19 (2): 240–48. doi:10.1016/S1470-2045(18)30011-1.